Aplastic Anemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Aplastic Anemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Aplastic Anemia - Drugs In Development, 2022, provides an overview of the Aplastic Anemia (Hematological Disorders) pipeline landscape.

Aplastic anemia is a syndrome of bone marrow failure characterized by peripheral pancytopenia and marrow hypoplasia. Symptoms include fatigue, pale skin, rapid or irregular heart rate, shortness of breath with exertion, nosebleeds and bleeding gums, prolonged bleeding from cuts, skin rash, dizziness and headache. Risk factors include exposure to toxic chemicals, treatment with high-dose radiation or chemotherapy for cancer, certain blood diseases, autoimmune disorders and serious infections. Treatment includes immunosuppressants and stem cell transplant.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Aplastic Anemia - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Aplastic Anemia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Aplastic Anemia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Aplastic Anemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 1, 6, 2, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Aplastic Anemia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Aplastic Anemia (Hematological Disorders).
  • The pipeline guide reviews pipeline therapeutics for Aplastic Anemia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Aplastic Anemia (Hematological Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Aplastic Anemia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Aplastic Anemia (Hematological Disorders)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Aplastic Anemia (Hematological Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Aplastic Anemia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Aplastic Anemia – Overview
Aplastic Anemia – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Aplastic Anemia – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Aplastic Anemia – Companies Involved in Therapeutics Development
Acceleron Pharma Inc
Amgen Inc
ASC Therapeutics Inc
Bellicum Pharmaceuticals Inc
BioLineRx Ltd
Cell Source Inc
Cellenkos Inc
F. Hoffmann-La Roche Ltd
Gamida Cell Ltd
Hangzhou Zede Pharmaceutical Technology Co Ltd
HemoGenyx Pharmaceuticals Plc
Jiangsu Hengrui Medicine Co Ltd
Novartis AG
Ono Pharmaceutical Co Ltd
Pfizer Inc
Regen BioPharma Inc
Regeneron Pharmaceuticals Inc
Aplastic Anemia – Drug Profiles
anti-thymocyte globulin (equine) – Drug Profile
Cell Therapy for Aplastic Anemia and Leukemia – Drug Profile
Cellular Immunotherapy for Aplastic Anemia – Drug Profile
Cellular Immunotherapy for Hematological Disorders – Drug Profile
ceralifimod – Drug Profile
CK-0801 – Drug Profile
CN-128 – Drug Profile
CordIn – Drug Profile
eltrombopag olamine – Drug Profile
Expanded Autologous T Regulatory Cells – Drug Profile
Gene Therapy for Aplastic Anemia – Drug Profile
Gene Therapy to Activate Telomerase for Aplastic Anemia and Pulmonary Fibrosis – Drug Profile
HemaXellerate – Drug Profile
Hetrombopag Olamine – Drug Profile
motixafortide acetate – Drug Profile
omidubicel – Drug Profile
REGN-7257 – Drug Profile
rivogenlecleucel – Drug Profile
romiplostim – Drug Profile
sotatercept – Drug Profile
Aplastic Anemia – Dormant Projects
Aplastic Anemia – Discontinued Products
Aplastic Anemia – Product Development Milestones
Featured News & Press Releases
May 12, 2021: Regen Biopharma announces consulting agreement with Biotech Research Group
Jan 11, 2021: Gamida Cell to present full data from phase 3 Study of omidubicel at TCT, the Combined Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR
Dec 14, 2020: Gamida Cell provides regulatory update on Biologics License Application for Omidubicel
Dec 09, 2020: Gamida Cell provides pipeline update, including detailed results of pivotal phase 3 clinical study of omidubicel, and prepares to start BLA submission by end of 2020
Nov 04, 2020: Gamida cell announces data on omidubicel to be presented at 62nd ASH Annual Virtual Meeting
Apr 21, 2020: Hemogenyx Pharmaceuticals announces approval and issuance of European Hu-PHEC Patent
Feb 11, 2020: Hemogenyx Pharmaceuticals: Approval and issuance of U.S. Hu-PHEC Patent
Oct 17, 2019: The CHMP adopted a negative opinion recommending the refusal of a marketing authorisation for Revolade (eltrombopag)
Aug 01, 2019: Health ministry to reimburse Novartis’ Revolade treating severe aplastic anemia
Jun 28, 2019: Refusal of a change to the marketing authorisation for Revolade (eltrombopag)
Jun 25, 2019: Novartis has requested a re-examination of EMA’s opinion on Revolade
Jun 18, 2019: Kyowa Hakko Kirin receives the partial change approval of Romiplate for Aplastic Anemia in Japan
May 11, 2019: Novartis issues voluntary nationwide recall of Promacta 12.5 mg for oral suspension due to potential peanut contamination
Feb 21, 2019: Gamida cell presents initial data from phase 1/2 study of NiCord in severe aplastic anemia at 2019 TCT Annual Meeting
Feb 14, 2019: Gamida Cell to host conference call and webcast to review data from NiCord program being presented at 2019 TCT Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Table 1: Number of Products under Development for Aplastic Anemia, 2022
Table 2: Number of Products under Development by Companies, 2022
Table 3: Number of Products under Development by Universities/Institutes, 2022
Table 4: Products under Development by Companies, 2022
Table 5: Products under Development by Companies, 2022 (Contd..1)
Table 6: Products under Development by Universities/Institutes, 2022
Table 7: Number of Products by Stage and Target, 2022
Table 8: Number of Products by Stage and Mechanism of Action, 2022
Table 9: Number of Products by Stage and Route of Administration, 2022
Table 10: Number of Products by Stage and Molecule Type, 2022
Table 11: Aplastic Anemia – Pipeline by Acceleron Pharma Inc, 2022
Table 12: Aplastic Anemia – Pipeline by Amgen Inc, 2022
Table 13: Aplastic Anemia – Pipeline by ASC Therapeutics Inc, 2022
Table 14: Aplastic Anemia – Pipeline by Bellicum Pharmaceuticals Inc, 2022
Table 15: Aplastic Anemia – Pipeline by BioLineRx Ltd, 2022
Table 16: Aplastic Anemia – Pipeline by Cell Source Inc, 2022
Table 17: Aplastic Anemia – Pipeline by Cellenkos Inc, 2022
Table 18: Aplastic Anemia – Pipeline by F. Hoffmann-La Roche Ltd, 2022
Table 19: Aplastic Anemia – Pipeline by Gamida Cell Ltd, 2022
Table 20: Aplastic Anemia – Pipeline by Hangzhou Zede Pharmaceutical Technology Co Ltd, 2022
Table 21: Aplastic Anemia – Pipeline by HemoGenyx Pharmaceuticals Plc, 2022
Table 22: Aplastic Anemia – Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
Table 23: Aplastic Anemia – Pipeline by Novartis AG, 2022
Table 24: Aplastic Anemia – Pipeline by Ono Pharmaceutical Co Ltd, 2022
Table 25: Aplastic Anemia – Pipeline by Pfizer Inc, 2022
Table 26: Aplastic Anemia – Pipeline by Regen BioPharma Inc, 2022
Table 27: Aplastic Anemia – Pipeline by Regeneron Pharmaceuticals Inc, 2022
Table 28: Aplastic Anemia – Dormant Projects, 2022
Table 29: Aplastic Anemia – Discontinued Products, 2022
List of Figures
Figure 1: Number of Products under Development for Aplastic Anemia, 2022
Figure 2: Number of Products under Development by Companies, 2022
Figure 3: Number of Products by Top 10 Targets, 2022
Figure 4: Number of Products by Stage and Top 10 Targets, 2022
Figure 5: Number of Products by Top 10 Mechanism of Actions, 2022
Figure 6: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Figure 7: Number of Products by Routes of Administration, 2022
Figure 8: Number of Products by Stage and Top 10 Routes of Administration, 2022
Figure 9: Number of Products by Top 10 Molecule Types, 2022
Figure 10: Number of Products by Stage and Top 10 Molecule Types, 2022

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings